

Haematologica  
HAEMATOL/2018/206912  
Version 3

Efficacy of first-line treatments for multiple myeloma patients not eligible for stem cell transplantation - A Network Meta-analysis

Hedwig M. Blommestein, Chrissy H.Y. van Beurden-Tan, Margreet G. Franken, Carin A. Uyl-de Groot, Pieter Sonneveld, and Sonja Zweegman

Disclosures: Dr. Blommestein reports grants from Netherlands Organisation for Health Research and Development (ZonMw) project number: 152001020, during the conduct of the study; grants from Celgene BV, grants from Roche, grants from SkylineDX, outside the submitted work. Dr. van Beurden-Tan reports grants from ZonMw (The Netherlands Organisation for Health Research and Development), personal fees from Hematology Newsboard, outside the submitted work. Dr. Franken reports grants from Netherlands Organisation for Health Research and Development (ZonMw), during the conduct of the study; grants from Roche Nederland BV, grants from Daiichi Sankyo, grants from Abbvie, grants from PamGene, grants from Gilead Sciences Netherlands BV, grants from Svenska Cellulosa Aktiebolaget, outside the submitted work. Dr. Uyl-de Groot reports grants from Netherlands Organisation for Health Research and Development (ZonMw) project number: 152001020, during the conduct of the study; grants from Boehringer Ingelheim, grants from Celgene, grants from Janssen-Cilag, grants from Genzyme, grants from Astellas, grants from Sanofi, grants from Roche, grants from Astra Zeneca, grants from Amgen, grants from Gilead, grants from Merck, grants from Bayer, grants from Glycostem Therapeutics, outside the submitted work. Prof. Sonneveld reports grants and personal fees from Celgene, grants and personal fees from Janssen, grants from amgen, grants from takeda, from karyopharm, outside the submitted work. Dr. Zweegman reports other from Janssen, other from Takeda, other from Celgene, during the conduct of the study; other from Janssen, other from Takeda, other from Celgene, outside the submitted work.

Contributions: HB, CvB, MF, CU, PS, SZ contributed to the conception and design of the study. HB and CvB obtained data, performed the analysis, and interpreted the data. HB wrote the first draft of the manuscript. CvB, MF, CU, PS, and SZ analyzed the results and revised the manuscript critically for important intellectual content. All authors read and approved the final version of the manuscript.